Zobrazeno 1 - 10
of 202
pro vyhledávání: '"Keith A. Rodvold"'
Autor:
Veda Diwadkar-Navsariwala, Janet A. Novotny, David M. Gustin, Jeffery A. Sosman, Keith A. Rodvold, James A. Crowell, Maria Stacewicz-Sapuntzakis, Phyllis E. Bowen
Publikováno v:
Journal of Lipid Research, Vol 44, Iss 10, Pp 1927-1939 (2003)
A physiological pharmacokinetic model was developed to describe the disposition of lycopene, delivered as a tomato beverage formulation in five graded doses (10, 30, 60, 90, or 120 mg), for a phase I study in healthy male subjects (five per dose). Bl
Externí odkaz:
https://doaj.org/article/39a08f7bebb64d08a279a91a3d572f62
Autor:
Keith A. Rodvold, Mark H. Gotfried, Vipul Gupta, Amanda Ek, Praveen Srivastava, Angela Talley, Jon Bruss
Publikováno v:
Antimicrob Agents Chemother
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug being developed for the treatment of serious bacterial infections. The active moiety, tebipenem, has broad-spectrum activity against common Enterobacterales pathogens, includin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c20b2294c02e84617215809257aae08
https://pubmed.ncbi.nlm.nih.gov/35762796
https://pubmed.ncbi.nlm.nih.gov/35762796
Publikováno v:
Open Forum Infectious Diseases. 9
Background SPR206 is a novel intravenously (IV)-administered next-generation polymyxin being developed for the treatment of multi-drug resistant (MDR) Gram-negative (GN) infections. A Phase 1 bronchoalveolar lavage (BAL) study was conducted to evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47c73cff092960a570f59201d4d63d7f
https://doi.org/10.1093/ofid/ofac492.677
https://doi.org/10.1093/ofid/ofac492.677
Autor:
Keith A. Rodvold, Emily N. Drwiega
Publikováno v:
Clinical Pharmacokinetics
A comprehensive review of drug penetration into pulmonary epithelial lining fluid (ELF) was previously published in 2011. Since then, an extensive number of studies comparing plasma and ELF concentrations of antibacterial agents have been published a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82fadcf48a50b13379e69e0299782300
https://doi.org/10.1007/s40262-021-01061-7
https://doi.org/10.1007/s40262-021-01061-7
Autor:
Anju Menon, Simon Portsmouth, Yuko Matsunaga, Richard G. Wunderink, Keith A. Rodvold, David P. Nicolau, Toshihiro Wajima, Roger Echols, Takayuki Katsube
Publikováno v:
Journal of Antimicrobial Chemotherapy
ObjectivesLung penetration of cefiderocol, a novel siderophore cephalosporin approved for treatment of nosocomial pneumonia, has previously been evaluated in healthy subjects. This study assessed the intrapulmonary pharmacokinetic profile of cefidero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed8c79503b27012e9ceb8a0e0d9bc88
https://doi.org/10.1093/jac/dkab280
https://doi.org/10.1093/jac/dkab280
Autor:
Gina Patel, Keith A. Rodvold, Vipul K. Gupta, Jon Bruss, Leanne Gasink, Floni Bajraktari, Yang Lei, Akash Jain, Praveen Srivastava, Angela K. Talley
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug antimicrobial agent with broad-spectrum activity that includes multidrug-resistant (MDR) Enterobacterales . This study evaluated the safety, tolerability, and pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b4e414d088b90d019506bbdeb97c12
https://doi.org/10.1128/aac.02407-21
https://doi.org/10.1128/aac.02407-21
Autor:
Jennifer Le, Manjunath P. Pai, Catherine Liu, Michael J. Rybak, Thomas P. Lodise, Benjamin M. Lomaestro, Donald P. Levine, Annie Wong-Beringer, John S. Bradley, Holly D. Maples, Keith A. Rodvold, John C. Rotschafer, Bruce A. Mueller
Publikováno v:
J Pediatric Infect Dis Soc
Background Recent vancomycin PK/PD and toxicodynamic studies enable a reassessment of the current dosing and monitoring guideline in an attempt to further optimize the efficacy and safety of vancomycin therapy. The area-under-the-curve to minimum inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c361ddbbe50d9f51edc91abb26e82f78
https://doi.org/10.1093/jpids/piaa057
https://doi.org/10.1093/jpids/piaa057
Autor:
Catherine Liu, Thomas P. Lodise, John S. Bradley, Michael J. Rybak, Keith A. Rodvold, Donald P. Levine, John C. Rotschafer, Jennifer Le, Bruce A. Mueller, Benjamin M. Lomaestro, Manjunath P. Pai, Holly D. Maples, Annie Wong-Beringer
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 40:363-367
Background Recent vancomycin PK/PD and toxicodynamic studies enable a reassessment of the current dosing and monitoring guideline in an attempt to further optimize the efficacy and safety of vancomycin therapy. The area-under-the-curve to minimum inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34e47d7fb1394c00e1b08b1b68b6f976
https://doi.org/10.1002/phar.2376
https://doi.org/10.1002/phar.2376
Publikováno v:
Clinical Pharmacokinetics. 59:409-425
Omadacycline is a novel aminomethylcycline antibiotic (antibacterial). Omadacycline has had chemical structure modifications at the C9 and C7 positions of the core tetracycline rings that allow stability in the efflux pump and ribosomal protection pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64cf2c0bd071ab7783ded7900ebf4113
https://doi.org/10.1007/s40262-019-00843-4
https://doi.org/10.1007/s40262-019-00843-4
Autor:
Manjunath P. Pai, Keith A. Rodvold
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Oral and intravenous (IV) omadacycline formulations are approved in the United States for treating acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults. Oral omadacycline bioavailability is 34.5%; si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5f10b11ade4e644e1b7dad647dc04c4
https://doi.org/10.1093/cid/ciz309
https://doi.org/10.1093/cid/ciz309